Cocrystal Pharma, Inc.
COCP
$1.31
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -52.26% | -22.70% | 53.80% | -24.49% | 29.81% |
| Gross Profit | 52.26% | 22.70% | -53.80% | 24.49% | -29.81% |
| SG&A Expenses | -14.72% | -2.65% | -25.88% | 0.33% | 15.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -42.99% | -16.56% | 25.56% | -18.65% | 25.86% |
| Operating Income | 42.99% | 16.56% | -25.56% | 18.65% | -25.86% |
| Income Before Tax | 26.84% | -18.58% | -28.25% | 23.76% | 0.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.84% | -18.58% | -28.25% | 23.76% | 0.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.84% | -18.58% | -28.25% | 23.76% | 0.82% |
| EBIT | 42.99% | 16.56% | -25.56% | 18.65% | -25.86% |
| EBITDA | 43.09% | 16.33% | -26.16% | 18.55% | -26.31% |
| EPS Basic | 26.49% | -18.36% | -26.89% | 38.98% | 20.99% |
| Normalized Basic EPS | 39.96% | 14.51% | -26.87% | 38.99% | 3.30% |
| EPS Diluted | 26.49% | -18.36% | -26.89% | 39.06% | 20.99% |
| Normalized Diluted EPS | 39.96% | 14.51% | -26.87% | 38.99% | 3.30% |
| Average Basic Shares Outstanding | -0.46% | 0.21% | 1.08% | 24.94% | 25.52% |
| Average Diluted Shares Outstanding | -0.46% | 0.21% | 1.08% | 24.94% | 25.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |